Skip to main content

Table 2 Changes in blood lipid parameters from baseline to final on-treatment assessment

From: A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Parameter, mmol/L Placebo
(n = 21)
Volixibat
5 mg b.i.d.
(n = 9)
10 mg q.d.
(n = 9)
20 mg q.d.
(n = 9)
2–5–10–20 mg q.d.
(n = 9)
30 mg q.d.
(n = 9)
40 mg q.d.
(n = 9)
80–40–20 mg q.d.
(n = 9)
Total
(n = 63)
Total cholesterol −0.20
(− 1.0, 1.7)
−0.90
(− 2.0, 0.3)
−0.40
(− 2.8, 0.4)
−0.70
(− 2.0, − 0.1)
−0.10
(− 0.8, 0.2)
−0.60
(− 1.4, 0.3)
−1.30
(− 1.8, − 0.1)
−1.00
(− 1.5, − 0.6)
−0.70
(− 2.8, 0.4)
LDL cholesterol 0.0260
(− 1.088, 1.838)
−0.9190
(− 1.502, − 0.233)
−0.2975
(− 2.719, 0.570)
−0.7520
(− 1.761, − 0.130)
−0.4925
(− 0.699, 0.156)
−0.6990
(− 1.451, 0.103)
−1.2690
(− 3.341, − 0.337)
−0.8030
(− 1.476, − 0.518)
−0.6990
(− 3.341, 0.570)
HDL cholesterol − 0.030
(− 0.49, 0.73)
−0.050
(− 0.38, 0.23)
−0.080
(− 0.85, 0.18)
0.000
(− 0.26, 0.18)
0.120
(− 0.03, 0.33)
0.130
(0.00, 0.23)
0.030
(− 0.21, 0.33)
−0.050
(− 0.16, 0.16)
0.000
(− 0.85, 0.33)
Triglycerides 0.000
(− 2.49, 1.00)
0.190
(− 0.11, 3.05)
0.210
(− 0.50, 2.08)
−0.130
(− 0.68, 1.45)
−0.120
(− 0.31, 1.20)
0.060
(− 0.10, 0.32)
−0.010
(− 0.76, 1.24)
−0.200
(− 0.45, 0.05)
−0.010
(− 0.76, 3.05)
VLDL cholesterol 0.0
(−1, 1)
0.0
(0, 1)
0.0
(−1, 1)
0.0
(0, 1)
0.0
(−1, 0)
0.0
(0, 1)
0.0
(−1, 2)
0.0
(− 1, 0)
0.0
(− 1, 2)
  1. Values are median (range). Baseline was the last observation before the first dose of study drug. Data are from the safety analysis set
  2. b.i.d., twice daily; HDL, high-density lipoprotein; LDL, low-density lipoprotein; q.d., once daily; VLDL, very low-density lipoprotein